-
平臺(tái)編號(hào)：bio-68824
-
國(guó)際編號(hào)：CRL-2651?
-
細(xì)胞信息： 203-7D10
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
203-7D10
ATCC Number：CRL-2651?
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG2a; IgG2b
運(yùn)輸方式：凍存運(yùn)輸
數(shù)量：大量
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
規(guī)格：0.5mg Designations: 203-7D10
Depositors: ?National Cancer Institute
Isotype: IgG2a; IgG2b
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension but many cells attach
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against a synthetic v-src oncogene peptide
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with a synthetic polypeptide with the sequence (C)GSSKSKPKDPSQRRHS corresponding to peptides 2 to 17 of the v-src oncogene.
Spleen cells were fused with Sp2/0 myeloma cells.
In immunoblot screening, the antibody detects a 60 kd protein in the src transformed T2 cell line.
A number of additional proteins are also detected in cell lines and embryo tissues including a 50 kd protein in the urine of cancer patients as well as the amniotic fluid of pregnant patients.
The reactivity of the antibody with the src peptide (2-17) was confirmed by ELISA.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml.
Maintain cell density between 2 X 10 exp5 and 2 X 10 exp6 viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 21967: Niman HL, Lerner RA. Polypeptide-induced monoclonal receptors to protein ligands. US Patent 5,015,571 dated May 14 1991
是否是腫瘤細(xì)胞：0
物種來(lái)源：小鼠
細(xì)胞形態(tài)：淋巴樣
免疫類型：IgG2a; IgG2b
運(yùn)輸方式：凍存運(yùn)輸
數(shù)量：大量
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)
規(guī)格：0.5mg Designations: 203-7D10
Depositors: ?National Cancer Institute
Isotype: IgG2a; IgG2b
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension but many cells attach
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against a synthetic v-src oncogene peptide
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with a synthetic polypeptide with the sequence (C)GSSKSKPKDPSQRRHS corresponding to peptides 2 to 17 of the v-src oncogene.
Spleen cells were fused with Sp2/0 myeloma cells.
In immunoblot screening, the antibody detects a 60 kd protein in the src transformed T2 cell line.
A number of additional proteins are also detected in cell lines and embryo tissues including a 50 kd protein in the urine of cancer patients as well as the amniotic fluid of pregnant patients.
The reactivity of the antibody with the src peptide (2-17) was confirmed by ELISA.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml.
Maintain cell density between 2 X 10 exp5 and 2 X 10 exp6 viable cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 21967: Niman HL, Lerner RA. Polypeptide-induced monoclonal receptors to protein ligands. US Patent 5,015,571 dated May 14 1991
